Table 1 Demographics, clinical, laboratory data, medication data on admission
Patient characteristics | CKI only (n = 238) | CA-ACKI (n = 104) | CA-AKI only (n = 237 | p |
|---|---|---|---|---|
Mean age (yr) ± SD Median (yr) + IQR | 79.7 ± 11.4 82 (74–88) | 79.5 ± 12.8 83 (73–89) | 72.8 ± 15.4 76 (64–84) | 0.001 |
Male gender (%) | 47 | 61 | 57 | 0.02 |
Diabetes (%) | 21 | 29 | 18 | 0.08 |
Hypertension (%) | 57 | 62 | 52 | 0.23 |
Coronaropathy (%) | 28 | 30 | 21 | 0.12 |
Cardiac Insufficiency (%) | 21 | 19 | 12 | 0.03 |
Cirrhosis (%) | 1 | 3 | 2 | 0.54 |
Cancer (%) | 8 | 9 | 14 | 0.09 |
Infection (%) | 4 | 7 | 11 | 0.01 |
AKI characteristics | ||||
Medical/Surgical/trauma (%) | 81/11/8 | 81/11/9 | 85/10/5 | 0.67 |
Stage 1/2/3 (%) | 42/41/16 | 79/17/4 | 0.001 | |
Prerenal/renal/postrenal/mixed (%) | 67/14/7/12 | 81/4/6/9 | 0.006 | |
Mean P-Creatinine (μmol/L) ± SD | 125 ± 55 | 270 ± 253 | 155 ± 96 | 0.001 |
eGFR (ml/mn) ± SD | 46 ± 11 | 27 ± 12 | 41 ± 13 | 0.001 |
Nephrotoxic drugs | ||||
RAA blockers (%) | 47 | 48 | 44 | 0.80 |
ACEIs (%) | 24 | 16 | 15 | 0.02 |
Low/medium-high doses (%) | 32/68 | 24/76 | 43/57 | 0.33 |
ARBs(%) | 28 | 34 | 23 | 0.08 |
Low/medium-high doses (%) | 26/74 | 37/63 | 17/83 | 0.07 |
Diuretics (%) | 40 | 53 | 35 | 0.008 |
Low/medium-high doses (%) | 73/27 | 50/50 | 61/39 | 0.02 |
RAA blockers + diuretics (%) | 25 | 24 | 26 | 0.99 |
NSAIDs (%) | 3 | 5 | 6 | 0.37 |
Antibiotics (%) | 2 | 1 | 6 | 0.04 |